Biocryst Pharmaceuticals (DE:BO1)

BioCryst Financial Statements


BioCryst Financial Overview

BioCryst's market cap is currently ―. The company's EPS TTM is €; its P/E ratio is ―; BioCryst is scheduled to report earnings on November 8, 2022, and the estimated EPS forecast is €-0.28. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Mar 22Dec 21Sep 21Jun 21
Income Statement
Total Revenue$ 65.53M$ 49.92M$ 47.16M$ 40.99M$ 49.96M
Gross Profit$ 65.28M$ 49.69M$ 46.74M$ 40.38M$ 49.62M
EBIT$ -33.98M$ -50.08M$ 3.25M$ -44.69M$ -29.70M
EBITDA$ -33.65M$ -49.76M$ 3.42M$ -44.46M$ -29.50M
Net Income Common Stockholders$ -58.86M$ -74.20M$ -17.78M$ -58.80M$ -43.20M
Balance Sheet
Cash, Cash Equivalents and Short-Term Investments$ 143.32M$ 199.60M$ 218.43M$ 240.36M$ 300.37M
Total Assets$ 510.54M$ 527.72M$ 588.15M$ 265.76M$ 277.28M
Total Debt$ 32.63M$ 129.00M$ 133.03M$ 168.07M$ 181.72M
Net Debt$ -110.69M$ -70.59M$ -85.40M$ -72.29M$ -118.65M
Total Liabilities$ 723.77M$ 691.93M$ 695.14M$ 412.81M$ 383.36M
Stockholders Equity$ 33.64M$ -213.23M$ -164.22M$ -106.99M$ -147.04M
Cash Flow
Free Cash Flow$ -28.00M$ -78.21M$ -33.57M$ -23.64M$ -26.22M
Operating Cash Flow$ -27.76M$ -77.80M$ -32.46M$ -23.28M$ -25.41M
Investing Cash Flow$ -97.44M$ -38.47M$ -11.12M$ 7.75M$ 4.50M
Financing Cash Flow$ 147.00K$ 7.36M$ 347.42M$ 4.78M$ 4.57M
Currency in USD

BioCryst Earnings and Revenue History

BioCryst Debt to Assets

BioCryst Cash Flow

BioCryst Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis